ABSTRACT
Alzheimer's disease (AD) is the most common form of dementia with a progressive course. AD pathology is a manifestation of the underlying severity and neuroanatomic involvement of specific vulnerable brain regions and circuits that are responsible for neuronal dysfunction and death. The etiology of AD is largely unknown. It has been hypothesized that multiple factors, including genetic components, oxidative stress, intracellular or extracellular accumulation of amyloid, dysfunction of cystoskeletal and synapse components, neuronal loss by apoptosis, neuronal excitotoxicity, inflammation, mitochondria dysfunction, etc., may play important roles in the onset of the disease. WWOX/WOX1 is a candidate tumor suppressor. Human WWOX gene, encoding the WW domain-containing oxidoreductase (designated WWOX, FOR, or WOX1) protein, has been mapped to a fragile site on the chromosome ch16q23.3-24.1. Functionally, the WW domain is not only a tumor suppressor, but also a participant in molecular interactions, signaling, and apoptosis in many diseases. In this article, we review the potential mechanism by which WWOX/WOX1 may participate in the pathogenesis of AD with a focus on cell death signaling pathways in neurons.
INTRODUCTION
Alzheimer's disease (AD) is the most common cause of dementia in elderly populations, presenting as a progressive disorder with clinical, biological, and pathological features occurring along the entire cognitive spectrum from normal to end-stage disease (1). Aging is the best correlative risk factor for AD (2). The disease afflicts one in eight people age older than 65 and nearly one in two people over 85. The cause of AD is unknown. Aging is the biggest driving force behind Alzheimer's; some of the same factors that trigger heart disease-obesity, high cholesterol, and diabetes-also increase the risk of dementia. AD is pathologically characterized by the presence of extracellular senile plaques, which consist of a core of amyloid-beta peptide and intracellular neurofibrillary tangles (NFTs), as well as the selective loss of neurons and synaptic connections (3-6). The exact cause(s) that induce(s) these pathological characteristics are poorly understood. AD pathology has been hypothesized as being the result of 1) genetic mutation; 2) oxidative stress in neurons; 3) coupling signal transduction pathways of amyloid beta receptors; and 4) hyperphosphorylation of Tau, a microtubule associated protein (7-8). The pathological characteristics of AD are not independent events. The accumulation of oligomeric and fibrillar amyloid beta in neurons may induce a series of neuronal signal transduction events to promote Tau hyperphosphorylation (8-12). The hyperphosphorylated Tau loses the ability to bind to microtubules, which leads to the loss of neurons. It has been suggested that soluble phospho-Tau, but not aggregated Tau, is the primary factor for cellular toxicity. Aggregated Tau/NFTs containing neurons show prolonged longevity, suggesting the hypothesis of a neuroprotective role for NFTs (13, 14).
WW
domain-containing oxidoreductase (designated WWOX, FOR, or WOX1) is a candidate tumor suppressor. Human WWOX gene, encoding the WWOX/WOX1 protein, has been mapped to a fragile site on the chromosome ch16q23.3-24.1 (15-17). Loss of heterozygosity of this chromosomal region has been demonstrated in many types of cancers. The FHIT gene is also located on a chromosomal fragile site (18). The WWOX/WOX1 gene encodes a 414 amino acid protein of 46.6 kDa molecular weight (15-17). WWOX/WOX1 protein possesses a nuclear localization sequence, two Nterminal WW domains (containing conserved tryptophan residues) and a C-terminal short chain alcohol dehydrogenase/reductase (ADH/SDR) domain (15-17). WW domains have been shown to interact with a wide variety of signaling proteins and functioning as adaptor proteins, transcriptional co-activators, and ubiquitin ligases. Via its first WW domain, WWOX/WOX1 is able to associate with and modulate the functions of a spectrum of proline-rich ligand containing proteins, such as p53, p73, Erb-4, c-Jun N-terminal kinase (JNK), c-Jun, runt-related transcription factor 2, dishevelled homolog protein-2 (Dvl-2), ezrin, etc (19-27). However, upregulation of the proapoptotic p53 is independent of the WW domain and proline-rich ligand motifs (28). WWOX/WOX1 is more than just a tumor suppressor. WWOX/WOX1 enhances tumor necrosis factor (TNF) cytotoxicity by downregulation of the apoptosis inhibitors, Bcl-2 and Bcl-xL. Overexpression of the full-length WWOX/WOX1 or just its WW domain region induces apoptosis (17, 22, 28 
WW DOMAIN-CONTAINING PROTEINS
WW domains are 38-40 amino acid residue units that fold into a three-stranded beta-sheet structure. A flat binding surface for the proline-rich ligand is formed by conserved hydrophobic residues. The domain name is derived from two conserved Tryptophan residues spaced 20 to 22 residues apart within the consensus sequence (50-53). The functions of WW domains derive from recognition of proline-rich peptide motifs and phosphorylated serine/threonine-proline sites (52) (53) (54) 57) . WWOX/WOX1 and its binding partners are involved in many molecular processes, such as transcription, RNA processing, and cytoskeletal regulation, etc (54, 55). The WW domains can be arranged in tandem repeats at various distances in a single protein and function in a synergistic or an independent manner (56) . A schematic diagram of WWOX/WOX1 protein is shown in Figure 1 . Tyr33 phosphorylation in WWOX/WOX1 occurs when cells are exposed to TNF-alpha, TGF-beta, staurosporine, etoposide, UV irradiation, complement C1q, and sex hormones including estrogen and androgen (19, 22, 35, 49, 58, 59) . Downregulation of activated CDC42 kinase 1 by neuronal precursor cell-expressed developmentally downregulated 4-2, E3 ubiquitin ligase (NEDD4-2) prolongs the lifetime of WWOX/WOX1 (60, 61) . MDM2, an E3 ubiquitin ligase, is regulated by binding to WWOX, and is involved in central nervous system degeneration (19, 62). Peptidylprolyl cis/trans isomerase, NIMA-interacting 1 (Pin1), containing only a WW domain (63) , is involved in both cancer and Alzheimer's disease (64, 65) . Pin1 is upregulated in cancers but downregulated in Alzheimer's disease, and participates in immune regulation (66) .
Tauopathy and WWOX/WOX1 in AD
Tau is a microtubule-associated protein functioning to promote microtubule assembly and stabilize microtubules (67) . Microtubules are essential for the axonal transport of neurons (67) . Phosphorylation of Tau affects axonal flow and cell viability in mature and developing neurons (67 
Enzymes participating in WWOX/WOX1-mediated AD pathology
GSK3-beta participates in both Tau and amyloidal pathologies in AD (77) . Overexpression of GSK3-beta results in Tau hyperphosphorylation and neurodegeneration in conditional GSK3-beta transgenic mice (78) . Upregulation of GSK3-beta inhibits long-term potentiation with synapse-associated impairments in vitro (79) . Beta amyloid activates GSK-3 through the inhibition of protein kinase C (PKC) activity (80) . Peroxynitrite induces Alzheimer-like Tau modifications and accumulation in rat brain via GSK-3 activation (81) . Synergistic effects of protein kinase A (PKA), cyclindependent kinase 5 (CDK5), dual-specificity tyrosine phosphorylation-regulated kinase1A with GSK-3, and reciprocal functions of GSK-3 with protein phosphatase-2A (PP-2A), and protein phosphatase 5 (PP5) on Tau hyperphosphorylation have been proposed (82) . GSK3-beta, JNK1, CDK5, extracellular signal-regulated kinase (ERK), and several others are known to hyperphosphorylate Tau in vivo (32). In comparison with age-matched normal controls, we found that WWOX/WOX1, its isoform WOX2, and their Tyr33-phosphorylated forms are significantly downregulated, along with increased Tau hyperphosphorylation, in the AD hippocampal neurons (32). When WWOX/WOX1 expression was knocked down by siRNA in SK-N-SH cells, endogenous Tau in these cells became phosphorylated selectively at Thr212/Thr231 and Ser515/Ser516 along with enhanced phosphorylation of GSK3-beta (at Tyr 216) and ERK, and NFT formation. Phosphorylation of these residues can be found in the PHFTau and NFTs from clinical specimens (32).
WWOX/WOX1 interacts with Tau, JNK1 and GSK3-beta in the extracts of rat brains and cultured cells (32). Mapping analysis showed that WWOX/WOX1 binds Tau via its C-terminal ADH /SDR domain.
Heat shock proteins (HSPs) target and direct the non-repairable misfolded protein aggregates to the ubiquitin proteasomal pathway (75) . The E2 enzyme UbcH5B and C-terminus of the Hsc70-interacting protein (CHIP)-Hsc70 complex, also called Tau E3 ligase, ubiquitinized phosphorylated Tau extracted from AD brains in vitro. The ubiquitinated PHF-Tau is not degraded but deposited in the NFTs in AD brain (76) . Overexpression of CHIP in AD promotes degradation of the hyperphosphorylated Tau in rat brain and neuroblastoma N2a cells (77) .
Tau phosphorylation and WWOX/WOX1 in neuron survival
There has been controversy about the toxicity of Tau polymerization (82, 83) . Aggregated Tau is toxic to cells (84, 85) . The polymerized Tau proteins in vitro lose the biological activities in promoting microtubule assembly and binding to the microtubules (84) . On the other hand, there are reports showing that polymerization of Tau is not relevant to cell toxicity (82) . In mice that express mutant human Tau P301L , a prominent neuronal loss is shown in the hippocampal CA1 region. Suppression of mutant Tau expression prevents further neuronal loss without reducing neurofibrillary pathology (86) . The dissociation of neuronal loss and accumulation of neurofibrillary pathology imply that formation of NFTs may not necessarily lead to neuronal death. By quantitative analysis of neuronal loss and NFT formation for an estimation of disease duration, the presence of Tau filaments did not correlate directly with the death of individual neurons, suggesting that NFT may not be obligatory for death of CA1 hippocampal neurons in AD patients (87) (88) (89) . Tau phosphorylation is upregulated during oxidative stress by lipid peroxidation products (90) . Acute oxidative stress and mild heat stress induce the accumulation of dephosphorylated Tau in neuronal nuclei. Increased interaction of endogenous Tau with neuronal genomic DNA prevents heat stress-induced damage (91) . Therefore, the regulation of Tau phosphorylation in adult Figure 2 . WWOX/WOX1 participates in regulating AD pathology. Stress or proapoptotic factor stimulation results in increased WWOX/WOX1, ROS, and Tau expression in the neuron. WWOX/WOX1 is phosphorylated at tyrosine 33 which interacts with p53, JNK1, GSK3-beta, Zfra, MDM2, and C1q. Re-localized phosphorylated WWOX/WOX1 at tyrosine 33 to the nucleus can induce apoptosis. WWOX/WOX1 works synergistically with p53 and re-localizes to the mitochondria or nucleus to promote apoptosis, which can be blocked by Zfra and MDM2. JNK1 physically interacts with phosphorylated WWOX/WOX1 to block WWOX/WOX1-induced apoptosis. WWOX/WOX1also interacts with JNK1 and GSK3-beta to prevent Tau phosphorylation. C1q binds to phosphorylated Tau and amyloid beta. C1q/WOX1 signals result in the formation of WWOX/WOX1 and amyloid beta-containing fragments, which enhance amyloid aggregation and neurodegeneration. ROS promotes Tau hyperphosphorylation through ASK1 and JNK signaling. ROS alone also causes cell apoptosis. Amyloid beta, via GSK3-beta, induces Tau hyperphosphorylation. GSK3-beta is also involved in competitive phosphorylation of Tau and beta-catenin. WWOX/WOX1 partners with Wnt/beta-catenin through sequestration of Dvl proteins to inhibit GSK3-beta-mediated betacatenin phosphorylation. Translocation of beta-catenin to the nucleus inhibits apoptosis. Hyperphosphorylated Tau results in NFT containing "sick neuron", and subsequent neurodegeneration. Hyperphosphorylated Tau activates PP2A or PP5, and through indirect inhibition of BCL2-antagonist of cell death (Bad) and caspase transcription in the nucleus to protect the neuron from apoptosis. mammalian brain may represent a naturally-occurring process that is associated with neuroprotective mechanisms (92, 93, 95) .
Beta-catenin is a major component involved in Wnt signaling. Beta-catenin can be phosphorylated by GSK3-beta for creating a signal for rapid degradation via proteosomal pathway. The exact connection between Tau and beta-catenin phosphorylation in not known. It has been suggested that Tau and beta-catenin compete for GSK3-beta-mediated phosphorylation (67) . Increased Tau phosphorylation inhibits beta-catenin phosphorylation, thus facilitating the function of beta-catenin in preventing apoptosis (67) (Figure 2 ).
In AD brain, the mechanism for connecting degenerated neurons with spatial temporal-specific patterns of Tau hyperphosphorylation into cell death signaling remains to be established. WWOX/WOX1 may, through its regulation with Tau, GSK3-beta, JNK, Wnt/beta-catenin, stress-induced ROS, C1q, etc., participate in these signaling events in AD brains (32, 36, 59, 67, 90) . WWOX/WOX1 binds directly to Tau through its ADH/SDR domain as evident by yeast two-hybrid analysis (32). Silencing of WWOX/WOX1 by siRNA increases the binding of Tau to GSK3-beta and phosphorylation of Tau, indicating that WWOX/WOX1 may be involved in regulating GSK3-beta activity in cells (32). It has been demonstrated that inhibition of GSK3-beta plays an essential role in neuronal differentiation (94) . Overexpression of WWOX/WOX1 enhances the SH-SY-5Y cell differentiation with or without the treatment of retinoic acid (RA). RNAi-mediated knockdown of WWOX/WOX1 in RA-differentiated SH-SY-5Y cells caused a decrease in neurite outgrowth (unpublished data).
Activation of GSK3-beta leads to AD-like memory deficit and neuronal dysfunction and death similar to AD (96) (97) (98) . Inhibition of GSK3-beta activity by lithium salts protects against neuronal degeneration and death induced by amyloid beta and Tau hyperphosphorylation in vitro and in vivo (96) (97) (98) (99) . Inactivation of GSK by Wnt signaling prevents Tau phosphorylation in the GSKdependent epitopes (96, 100) . GSK3-beta maintains a hyperactive state in AD, which leads to the hyperphosphorylation of Tau. GSK3-beta regulates amyloid precursor protein (APP) metabolism and overproduction of amyloid beta, which results in reduced neurogenesis and increased apoptosis (7). A neuronal protective hormone, 17-beta-estradiol increases the binding of WWOX/WOX1 and GSK-3 with Tau (32). Serine and threonine are function-associated phosphorylation sites of Tau (82) . Given that WW domains functions derive from recognition of proline-rich peptide motifs and phosphorylated serine/threonine-proline sites, detailed dissections of how WWOX/WOX1 is involved in modulate and regulate Tau phosphorylation and NFT formation at specific serine/threonine sites might shed light on how to prevent neurodegeneration.
Potential key linkers for Alzheimer's disease pathology and WWOX/WOX1
Tau is essential to amyloid beta-induced neurotoxicity (101) . Amyloid beta causes degeneration in Tau expressing neurons, but not in Tau-depleted neurons (102) .
Overloading amyloid beta induces hyperphosphorylated Tau in AD brains directly or indirectly. GSK3-beta is a key linker to the accumulation of amyloid beta and hyperphosphorylation of Tau (8). In a cell-free model in vitro, hyperphosphorylation of Tau by GSK3-beta is sufficient to cause tangle-like aggregates which are similar to NFT isolated from AD brains (103) . Transgenic mice overexpressing GSK-3beta induces Tau hyperphosphorylation and tangle-like filaments formation in hippocampal neurons as well as atrophy of the hippocampal dentate gyrus (104) . Active GSK3-beta levels in cortical neurons are increased at different stages of neurofibrillary degeneration (105) . Phosphorylation of Tau at Thr231 enhances subsequent hyperphosphorylation of Tau by GSK3-beta (80, 106) . Tau phosphorylation is also regulated by the interactions between WWOX/WOX1, GSK3-beta, JNK, and Wnt/beta-catenin (32, 36, 67, 90) . Tau phosphorylation is inhibited by the interaction between WWOX/WOX1, JNK1 and GSK3-beta (Figure 2) . The physical interactions between WWOX/WOX1, Tau, JNK1 and GSK3-beta have been demonstrated in the extracts of rat brains and cultured cells (32). These findings suggest that WWOX/WOX1 might participate in AD pathology through its protein binding partners. Figure 2 summarizes how WWOX/WOX1 interacts with its potential domain-binding partners to participate in AD pathology.
ROS and WWOX/WOX1 in AD
Reactive oxygen species (ROS) generated by beta amyloid disrupt mitochondrial respiration (107) (108) (109) . Mitochondrial damage promotes neurodegeneration and cell death (109) . The activation of apoptosis signal-regulating kinase 1 (ASK1) induces the activation of JNK and p38 MAPK. Amyloid beta induces neuronal cell death through ROS-mediated ASK1 activation (110) . The c-Jun kinase is a downstream effector of JNK and is associated with the activation of caspase-3 and neuronal apoptosis. The activation of JNK and p38 MAPK in AD-induced Tau phosphorylation generates Tau protein pathology but is not coupled with neuronal apoptosis through the c-Jun kinase pathway (111, 112) . How to explain this dissociation between neuronal loss and accumulation of neurofibrillary pathology in AD remains elusive. Mouse WWOX/WOX1 interacts with phosphorylated c-Jun in the sciatic axotomy neuronal injury in rat, which enhances the promoter activation governed by c-Jun (46) . On the other hand, WWOX/WOX1 inhibits apoptosis to protect neurons in a time-lapsed chronicled fashion in dorsal root ganglia of rat (46) . Whether this phenomenon would occur in cortical neuron, and JNK1 and WWOX/WOX1 interaction would induce oxidative stress and free radical is unknown.
Neuronal cell death signaling and WWOX/WOX1 in AD
Neuronal apoptosis occurs in AD brain. The apoptotic DNA fragmentation and expression of apoptotic signaling proteins are observed in the neocortices and hippocampi of postmortem AD brains (113) . Amyloid beta alone induces neuronal apoptosis in vitro (114) . The expression of TNF receptor I (TNFR1), a death receptor, is increased in AD and is related to the apoptotic process through its ligand, TNF-alpha (115) . TNF-alpha induces apoptosis through activation of Fas-associated protein with death domain (FADD), JNK or nuclear factor-kappaB (NF-κB). JNK is activated in AD patients and mouse models of AD, which is associated with expression of pro-apoptotic genes and activation of caspases-3 and caspase-9 (118). WWOX/WOX1 increases the cytotoxic function of TNF in killing cancer cells by interacting with TNFR1-associated death domain (TRADD)/FADD and TRAF2 (13, 28). TNFR1/FADD recruits TRAF2 that leads to NF-κB activation. In AD, amyloid beta peptide activates NF-κB and induces apoptosis (116, 117) . Amyloid beta peptides promote pathological Tau filament assembly and NFTs formation in neurons (119) . We found that rapid activation of JNK1 and WWOX/WOX1 during the acute phase of injury is critical for neuronal survival or death, however, chronic and concurrent activation of WOX1, CREB, and NF-κB occurs in small neurons just prior to apoptosis (46) . WWOX/WOX1 inhibits pro-survival CREB-, CRE-, and activator protein 1(AP-1)-mediated promoter activation in vitro. In contrast, WWOX/WOX1 enhances promoter activation governed by c-Jun, Elk-1(Ets Like gene1) and NF-κB (46) . WWOX/WOX1 directly activates NF-κB-regulated promoter via its WW domains (46) . Zfra (31-amino-acid zinc finger-like protein) interacts with death domain protein TRADD to regulate TNF-mediated cell death, and downregulates NF-kappaB, JNK1, p53 and WWOX/WOX1 during stress response (23). Zfra interferes with WWOX/WOX1 and p53-induced apoptosis by blocking its translocation to the mitochondria or nucleus (23).
WWOX/WOX1 is a proapoptotic protein, capable of interacting with p53 (19, 28, 33). p53 Figure 3 . WWOX/WOX1 participates in cell death signaling in Alzheimer's disease. Oligomeric/fibrillary amyloid beta aggregates are lethal to neurons through TNF/FAS ligand or JNK1 signaling pathways. WWOX/WOX1 enhances TNF apoptosis by interacting with FADD and TRAF2. TNF binds to the membrane p55 TNFR1, which recruits FADD and activates caspase 8, which in turn activates caspase 9, caspase 3 and downstream caspase 6 and 7. TNFR1/FADD recruits TRAF2 that leads to NF-κB activation. In a second link, TRAF2 activates apoptosis signal-regulating kinase 1 (ASK1), which in turn activates JNK.
WWOX/WOX1 blocks CREB and TRAF-2, which is followed by activation of NF-κB and JNK to inhibit apoptosis. The exact role of WWOX/WOX1 and these proteins' interactions in TNF signaling to balance the cell's fate between survival and death remains elusive. Phosphorylated WWOX/WOX1 at tyrosine 33 (pWOX1) either by translocation to the mitochondria or the nucleus to work directly or indirectly with amyloid beta or p53 to enhance apoptosis. pWOX1 interacts with JNK1 or GSK3-beta to inhibit Tau phosphorylation, which can either be protective or harmful to neurons in AD depending on the chronicle (acute or chronic) of Tau phosphorylation. WWOX/WOX1 also partners with the Wnt/beta-catenin through sequestration of Dvl proteins to inhibit GSK3-beta-mediated beta-catenin phosphorylation, which inhibits apoptosis. transcriptional activity depends on posttranslational modifications and protein-protein interaction. Homeodomain interacting protein kinase 2 (HIPK2) is an evolutionary conserved serine/threonine kinase to maintain wild-type p53 function (122) . Soluble beta amyloid peptides is involved in HIPK2 degradation, which results in misfolded p53 and altered vulnerability of cells to a noxious stimulus, suggesting that conformationally changed p53 can be a putative biomarker for AD (120, 121, 122) . Given that WWOX/WOX1 and p53 induce apoptosis synergistically, whether or not WWOX/WOX1 interacts with amyloid beta peptides or HIPK2 remains to be established. It is important to discerning the link between transient overexpression of WWOX/WOX1 ADH/SDR domain and accumulation of amyloid beta peptide, Tau phosphorylation, and formation of NFT. Also to determine how WWOX/WOX1 interacts with critical signaling proteins such as TNF-alpha, p53, JNK1, NF-κB, Wnt/betacatenin, Pin1, CREB, etc., to regulate cell death in vitro and in vivo might be the focus of future research to understand the role of WWOX/WOX1 in neurodegenerative cell death in AD. It is not clear whether or not WWOX/WOX1 participates in necrotic and autophagic cell death in AD. Figure 3 summarizes the potential role(s) of WWOX/WOX1 in cell death signaling in AD.
WWOX/WOX1 and inflammation in AD
C1q, a subcomponent of C1, is capable of binding to amyloid beta in the beta-sheet conformation and activate complement in vitro (123) . Absence of C1q leads to less neuropathology in transgenic mouse models of AD (124) . On the other hand, C1q protects early stages of neuronal injury by rapid clearance of apoptotic cells and/or cellular debris to prevent inflammation (125) . Tenner et al. reported that the contribution of complement activation pathways to neuropathology differs among mouse models of AD (124) . The alternative complement pathway activation of a C3-independent cleavage of C5 determines the progression of neuropathology in 3xTg mice versus other murine models (124) . C1q binds to hyperphosphorylated Tau and activated complement in vitro (126, 127) . In Down's syndrome with AD, compaction of amyloid beta 42 deposits activates the classical complement cascade, which progresses to make neuronal expression of the membrane attack complex (MAC) as a response to amyloid beta plaque maturation (128) . C1q binds to Tau and amyloid beta and is a potent facilitator of amyloid beta aggregation (123, 126, 128) . C1q is capable to activating WWOX/WOX1 bypassing the classical pathway activation (59) . When overexpressed, WWOX/WOX1 signals with C1q to induce apoptosis, which is followed by fragmentation of WWOX/WOX1-containing microvilli clusters formed in between prostate DU145 cells (59) . C1q alone signals WWOX/WOX1 activation for apoptosis. This event occurs only when cells have sufficient amounts of intracellular WWOX/WOX1 (59) . The underlying mechanism of how WWOX/WOX1 interacts with C1q in AD pathology and cell death signaling remains to be determined.
TGF-beta1 and WWOX/WOX1 in AD
TGF-beta1 is crucial in regulating neuroprotection and neurodegeneration (132) . Longterm overexpression of TGF-beta1 in mice causes neurodegeneration (132) . Many WW domaincontaining proteins participate in the TGF-beta signaling (35) . TGF-beta1 binds cell surface hyaluronidase Hyal-2 in in type II TGF-beta receptordeficient cells, followed by recruiting WWOX and mothers against decapentaplegic homolog 4 (Smad4) to regulate gene transcription, growth and death (49) . Recently, we have demonstrated that a small TGFbeta1-induced antiapoptotic factor (TIAF1) is involved in the pathogenesis of AD (129) . TGF-beta1 and environmental stress induces TIAF1 self aggregation in a type II TGF-beta receptorindependent manner in cells (129) . Smad4 interrupts the aggregation formation (129) . Aggregated TIAF1 induces apoptosis in a caspase-dependent manner. By filter retardation assay, TIAF1 aggregates were found in the hippocampi of non-demented humans and AD patients (129) . TGF-beta1 signals the binding of TIAF1 with Smad4 to form a complex, which relocates to the nuclei to modulate gene transcription. Smad4 is critical for supporting the generation of membrane APP via regulation of gene transcription (130, 131) . Furthermore, TIAF1 binds and stabilizes membrane APP. TGF-beta1 induces TIAF1 aggregation and reduces its binding with APP, and causes APP dephosphorylation (129) . Dephosphorylated APP undergoes enzymatic cleavage and subsequent production of amyloid beta monomer, intracellular domain of the APP intracellular domain (AICD), and amyloid fibrils (133) . Thus, a balanced state of phosphorylation of APP is critical in determining plaque formation. Overexpressed Smad4 alone induces apoptosis of cancer and neuronal cells. It seems that TGF-betainduced TIAF1 aggregation and Smad4-mediated APP gene activation occur concurrently (129) . TIAF1 aggregates bind to Smad4 to prevent nuclear relocation (129) . We suggest that TIAF1 aggregation occurs preceding generation of amyloid beta and amyloid fibrils, and the TIAF1/amyloid fibril aggregates facilitate plaque formation (129) . TGFbeta1 exerts neuroprotective or degenerative function depends on the duration of its exposure in transgenic mice (132) . Long-term TGF-beta1 exposure results in irreversible amyloid fibrils and apolipoprotein E (ApoE) depositions, even after silencing of the transgene or TGF-beta1 removal (132) . WOX1/WWOX and TIAF1 both participate in regulating the activation of Smad-driven promoter via the type II TGF-beta receptor-independent manner to induce apoptosis or neurodegeneration (49, 129) . This different outcome might relate to the Smad complex activation and duration of TGF-beta1 exposure. Further dissect the role of WWOX/WOX1 in TGF-beta induced TIAF1 self-aggregation and Smad4 overexpression in senile plaques formation might shed light for the development of therapeutic strategy in AD.
Conclusion and the future for WWOX/WOX1 in AD research
The interaction between WWOX/WOX1 and its binding partners determine the functioning roles of WWOX/WOX1 in neurodegeneration. Physical interaction of WWOX/WOX1 with Tau at the ADH/SDR domain and JNK at first WW domain regulate Tau phosphorylation in vitro and in vivo (22, 32). Knocked-down of WWOX/WOX1 expression by siRNA in SK-N-SH cells enhances Tau phosphorylation along with enhanced phosphorylation of GSK3-beta and ERK, and NFT formation (32). Ectopic expression of ADH/SDR domain of WWOX/WOX1 suppresses E2-induced Tau phosphorylation and increases TNF cytotoxicity in vitro (32). The findings suggest that WWOX/WOX1 prevents phosphorylation of Tau by interacting with JNK1, GSK-3, and other enzymes in vivo. Hyperactive GSK3-beta in AD leads to hyperphosphorylation of Tau. GSK3-beta also regulates APP metabolism, and is conducive to amyloidogenic cleavage (7). WWOX/WOX1 through sequestration of Dvl protein inhibits Wnt/beta-catenin pathway (26). Wnt signaling contributes to amyloid beta peptide-mediated neuropathology in AD by inactivate GSK, which prevents Tau phosphorylation in the GSK-dependent epitopes (96, 100) . GSK3-beta initiates proteosomal degradation of beta-catenin by phosphorylation of beta-catenin on key residues. Also, GSK3-beta has a nuclear function in downregulating the activity of beta-catenin (134) . It is apparent that WWOX/WOX1 might directly or indirectly partner with aforementioned signal transduction pathways to participate in the overloaded amyloid beta-induced Tau hyperphosphorylation and neural dysfunction or death, which is critical in the pathogenesis of AD. With these considerations in regard, downregulating or inhibiting WWOX/WOX1 expression might be used as a therapeutic intervention strategy in AD. However, because WWOX/WOX1 is also a tumor suppressor, whether this approach will induce tumorigensis requires further consideration.
Obesity, high cholesterol, and diabetes increase the risk of dementia. Those are problems on the rise in many developing countries and are areas of focus in AD research. WOX1/WWOX is associated with low plasma HDL C levels and the WWOX gene is associated with HDL cholesterol and triglyceride levels which are crucial for the development of metabolic syndrome, and increases the risk for AD (37) (38) (39) . Multiple metabolic defects occur in WWOX/WOX1-knockout mice suggesting WWOX/WOX1 may be a key regulator in different metabolic processes (40) (41) (42) 135) . Research of WW domain-containing proteins on metabolic syndrome may help to further understand the role of WWOX/WOX1 in AD.
In conclusion, WWOX/WOX1, through interactions with its protein partners, plays important roles as multitasked protein in regulating apoptosis, cell growth and proliferation, DNA damage/ repair, cell trafficking, metabolic reactions, and central nervous system pathology and degeneration, any one of which might play an important role in the pathogenesis of AD (25, 35, 36, 135) . This review only touches the tip of iceberg for the potential roles of WWOX/WOX1 in AD. We hope this review will bring up more researches to explore the role of WWOX/WOX1 in AD and other neurodegenerative diseases.
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